Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $14.33.

Seres Therapeutics Stock Performance

Shares of MCRB stock opened at $8.47 on Friday. The firm has a market capitalization of $76.65 million, a price-to-earnings ratio of -2.37 and a beta of 0.22. Seres Therapeutics has a one year low of $6.53 and a one year high of $29.98. The company has a 50 day moving average price of $14.89 and a 200 day moving average price of $16.78.

Institutional Investors Weigh In On Seres Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace LLP acquired a new stake in shares of Seres Therapeutics in the second quarter valued at about $1,016,000. Invesco Ltd. boosted its holdings in Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 89,995 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in Seres Therapeutics in the third quarter valued at approximately $557,000. XTX Topco Ltd purchased a new stake in shares of Seres Therapeutics during the second quarter valued at approximately $249,000. Finally, Goldman Sachs Group Inc. lifted its position in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 21,679 shares in the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.